Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritation Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating and Treating Potential Research Participants With Digestive Disorders

NCT01736280
View directory record Official record
Conditions
Stress, Irritable Bowel Syndrome, Obesity, Abdominal Pain
Interventions
Standard of Care
Other
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
2 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 4 Interventional

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

NCT00294255
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 14, 2026, 9:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children

NCT01675960
View directory record Official record
Conditions
Neurologically Impaired, Irritable Mood, Signs and Symptoms, Digestive, Sleeplessness, Chronic Pain
Interventions
Gabapentin, placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
1 Month to 16 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

NCT04135560
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
PF-07038124 and Vehicle, PF-07038124 or vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional

SMART Program in Irritable Bowel Syndrome (IBS)

NCT03454386
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Stress Management and Resilience Training Program, Self-Management Stress Reduction Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Atrantil for Intestinal Bacterial Overgrowth

NCT04755673
View directory record Official record
Conditions
Irritable Bowel Syndrome, Bacterial Overgrowth Syndrome, SIBO
Interventions
Atrantil (Medical Food)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 14, 2026, 9:14 AM EDT
Not yet recruiting Not applicable Interventional

Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C

NCT07662083
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS-C)
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 14, 2026, 9:14 AM EDT
Terminated Phase 1 Interventional

The Use of VSL#3 in Irritable Bowel Syndrome in Children

NCT00932841
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, VSL#3 900 billion bacteria, VSL#3 90 billion bacteria
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 14, 2026, 9:14 AM EDT
Completed No phase listed Observational

Biopsychosocial Contributors to Irritability in Individuals With Shoulder Pain

NCT06429371
View directory record Official record
Conditions
Shoulder Pain
Interventions
Quantitative Sensory Testing, Pain-Related Psychological Factors
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

NCT00269412
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 14, 2026, 9:14 AM EDT
Terminated Phase 4 Interventional Results available

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

NCT03750656
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Hyoscyamine, Tamsulosin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 14, 2026, 9:14 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Virtual Reality (VR) for Irritable Bowel Syndrome

NCT06257472
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Virtual Reality Headset
Device
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study

NCT03252522
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo
Combination Product · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 12 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

NCT05482464
View directory record Official record
Conditions
Inflammatory Bowel Syndrome
Interventions
Casein glycomacropeptide (CGMP)
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

NCT00554320
View directory record Official record
Conditions
Chronic Pelvic Pain, Interstitial Cystitis, Post Traumatic Stress Disorder, Fibromyalgia, Irritable Bowel Syndrome
Interventions
tDCS
Procedure
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional Results available

Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data

NCT00880256
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
mindfulness-based stress reduction
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 14, 2026, 9:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Examining the Impacts on In-School Behaviors of In-Home Videogame Play

NCT05260398
View directory record Official record
Conditions
Emotional Regulation, Problem Behavior, Irritable Mood
Interventions
Mightier Online Gameplay
Behavioral
Lead sponsor
Neuromotion Labs
Industry
Eligibility
6 Years to 11 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Not applicable Interventional

RCT of VR Therapy for IBS

NCT06687616
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
SynerGI, Sham VR
Device
Lead sponsor
Christopher Almario
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Recruiting Phase 2 Interventional

The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT06211062
View directory record Official record
Conditions
ME/CFS, IBS - Irritable Bowel Syndrome
Interventions
Floradapt Intensive GI, Placebo
Drug · Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 14, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional

Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms

NCT05414708
View directory record Official record
Conditions
PTSD, Military Activity, Post-Traumatic Headache, Posttraumatic Stress Disorder, Posttraumatic Stress Disorder, Delayed Onset, Sleep Disturbance, Nightmare, Irritable Mood, Anger, Combat and Operational Stress Reaction, Combat Stress Disorders, Military Family, Military Operations, Emotional Regulation, Emotion Processing
Interventions
Art Therapy
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 14, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320
View directory record Official record
Conditions
Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions
Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 14, 2026, 9:14 AM EDT